CAR-20-19-22

N/A

Report date: 2024/09/21 20:00:09

Base Information

Drug NameCAR-20-19-22

Drug Alias NameAnti-CD20, Anti-CD19, Anti-CD22 CAR (CAR20.19.22) T-cellsCAR20.19.22CAR-20-19-22

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD20Anti-CD19Anti-CD22

TargetsB-lymphocyte antigen CD20B-lymphocyte antigen CD19CD22

Therapy Area/IndicationsLymphoma, B-CellLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesThe Medical College Of Wisconsin Nonprofit

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesThe Medical College Of Wisconsin Nonprofit

Active IndicationsN/A

Inactive IndicationsLymphoma, B-CellLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A